Of the wide selection of therapeutic goals, our first study of vanicoside A and B activity against melanoma focused on the V600E BRAF and MEK1 molecules taking into account the big impact of potential inhibitors of these kinase on melanoma therapy and also other cancers like colon adenocarcinoma, papillary thyroid carcinoma and others [20]. The gene discussed is BRAF; the disease is cancer.